Earlier this year the Innovative Genomics Institute and the life sciences tools conglomerate Danaher launched a collaborative center to develop genome-editing therapies for rare and other diseases. The Danaher-IGI Beacon for CRISPR Cures seeks to address hundreds of diseases with a unified research, development, and regulatory approach. Their goal is to create a new model for the development of genomic medicines. We spoke to Fyodor Urnov, IGI’s director of technology and translation and director of the new Beacon center, about the evolution of gene editing technology, the challenges of a platform approach, and how the organization plans to share what it learns.
Keeping the Sentinels of the Brain Vigilant
Considering the Unfinished Work in Cystic Fibrosis
How to Advocate for Yourself as You Battle Cancer
Targeting Neuroinflammation to Treat ALS
Leveraging Community Partnerships to Address a Rare Disease Behind a Medical Mystery in New Mexico
Accelerating Gene Editing Therapies for Rare, Neurological Conditions
Inhibiting Electrical Activity in Rare, Seizure Disorders
Improving the Function and Usability of Clothing for People with Disabilities
Treating Cardiopulmonary Disease with Inhaled Targeted Therapies
A Patient-Driven Registry Focused on Health-Related Quality of Life Data
An Ally for the Undiagnosed Emerges
Help for Rare Disease Patients That’s Just a Click Away
Diagnosing Autism with a Single Strand of Hair
Bringing Regenerative Medicine to a Rare Bone Condition in Children
Bringing Precision to CRISPR-Based Genome Editing
Capturing Patients’ Experience in Their Daily Lives
From One to Many
A Nasal Spray to Curb Excessive Eating in Prader-Willi
How One Foundation Is Laying the Groundwork to Advance Treatments for an Ultra-Rare Disease
Forging a New Path for Medicine
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
NABOR® TALKS
U.S Property Podcast
Aligned Money Show
The Ramsey Show
Planet Money